Show simple item record

Analýza TRAILem indukované apoptózy u buněk akutní myeloidní leukémie
dc.contributor.advisorNečas, Emanuel
dc.creatorKlener, Pavel
dc.date.accessioned2018-09-18T08:21:10Z
dc.date.available2018-09-18T08:21:10Z
dc.date.issued2007
dc.identifier.urihttp://hdl.handle.net/20.500.11956/12267
dc.description.abstractAdvanced tumors, including leukemia, represent heterogeneous cell populations evolved from original malignant clones. Chemotherapy of leukemia is often associated with selection of drug-resistant cells followed by progression/relapse of the disease. Implementation of molecules that specifically target leukemia cells with minimal toxicity to normal tissues might significantly improve outcome of leukemia treatment. TRAIL belongs to the tumor necrosis factor (TNF) ligand family of cytokines. TRAIL triggers apoptosis in target cells via the receptor-mediated apoptotic pathway. Receptors for TRAIL can be divided into death receptors, TRAILR1/ DR4 , TRAIL-R2/DR5, and decoy receptors, TRAIL-R3/DcR1, TRAIL-R4/DcR2, osteoprotegerin/OPG/TRAIL-R5, based on their ability to transduce apoptotic signal. While normal tissues, including hematopoietic progenitor cells, are resistant to TRAIL-induced apoptosis, TRAIL induces programmed death in many tumor cell lines and primary cells. Various malignant cell lines and primary tumor cells, however, show resistance to TRAIL-induced apoptosis. TRAIL-resistance could represent important limitation for the potential TRAIL anti-tumor therapy. Combined in vitro application of TRAIL with other anti-cancer agents often increased sensitivity or overcame resistance of the tumor cells to...en_US
dc.languageEnglishcs_CZ
dc.language.isoen_US
dc.publisherUniverzita Karlova, 1. lékařská fakultacs_CZ
dc.titleAnalysis of TRAIL-induced apoptosis in acute myeloid leukemia cellsen_US
dc.typedizertační prácecs_CZ
dcterms.created2007
dcterms.dateAccepted2007-11-29
dc.description.departmentInstitute of Pathological Physiology First Faculty of Medicine Charles University in Pragueen_US
dc.description.departmentÚstav patologické fyziologie 1. LF UK v Prazecs_CZ
dc.description.facultyFirst Faculty of Medicineen_US
dc.description.faculty1. lékařská fakultacs_CZ
dc.identifier.repId123087
dc.title.translatedAnalýza TRAILem indukované apoptózy u buněk akutní myeloidní leukémiecs_CZ
dc.contributor.refereeHerget, Jan
dc.contributor.refereeTrka, Jan
dc.identifier.aleph000966653
thesis.degree.namePh.D.
thesis.degree.leveldoktorskécs_CZ
thesis.degree.discipline-cs_CZ
thesis.degree.discipline-en_US
thesis.degree.programHuman Physiology and Pathophysiologyen_US
thesis.degree.programFyziologie a patofyziologie člověkacs_CZ
uk.faculty-name.cs1. lékařská fakultacs_CZ
uk.faculty-name.enFirst Faculty of Medicineen_US
uk.faculty-abbr.cs1.LFcs_CZ
uk.degree-discipline.cs-cs_CZ
uk.degree-discipline.en-en_US
uk.degree-program.csFyziologie a patofyziologie člověkacs_CZ
uk.degree-program.enHuman Physiology and Pathophysiologyen_US
thesis.grade.csProspěl/acs_CZ
thesis.grade.enPassen_US
uk.abstract.enAdvanced tumors, including leukemia, represent heterogeneous cell populations evolved from original malignant clones. Chemotherapy of leukemia is often associated with selection of drug-resistant cells followed by progression/relapse of the disease. Implementation of molecules that specifically target leukemia cells with minimal toxicity to normal tissues might significantly improve outcome of leukemia treatment. TRAIL belongs to the tumor necrosis factor (TNF) ligand family of cytokines. TRAIL triggers apoptosis in target cells via the receptor-mediated apoptotic pathway. Receptors for TRAIL can be divided into death receptors, TRAILR1/ DR4 , TRAIL-R2/DR5, and decoy receptors, TRAIL-R3/DcR1, TRAIL-R4/DcR2, osteoprotegerin/OPG/TRAIL-R5, based on their ability to transduce apoptotic signal. While normal tissues, including hematopoietic progenitor cells, are resistant to TRAIL-induced apoptosis, TRAIL induces programmed death in many tumor cell lines and primary cells. Various malignant cell lines and primary tumor cells, however, show resistance to TRAIL-induced apoptosis. TRAIL-resistance could represent important limitation for the potential TRAIL anti-tumor therapy. Combined in vitro application of TRAIL with other anti-cancer agents often increased sensitivity or overcame resistance of the tumor cells to...en_US
uk.file-availabilityV
uk.publication-placePrahacs_CZ
uk.grantorUniverzita Karlova, 1. lékařská fakulta, Ústav patologické fyziologie 1. LF UK v Prazecs_CZ
thesis.grade.codeP


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


© 2017 Univerzita Karlova, Ústřední knihovna, Ovocný trh 3-5, 116 36 Praha; email: admin-repozitar [at] cuni.cz

Za dodržení všech ustanovení autorského zákona jsou zodpovědné jednotlivé složky Univerzity Karlovy. / Each constituent part of Charles University is responsible for adherence to all provisions of the copyright law.

Upozornění / Notice: Získané informace nemohou být použity k výdělečným účelům nebo vydávány za studijní, vědeckou nebo jinou tvůrčí činnost jiné osoby než autora. / Any retrieved information shall not be used for any commercial purposes or claimed as results of studying, scientific or any other creative activities of any person other than the author.

DSpace software copyright © 2002-2015  DuraSpace
Theme by 
@mire NV